HR 6625 117th Congress House Health Cardiovascular and respiratory health Civil actions and liability Department of Health and Human Services Drug therapy Emergency medical services and trauma care Federal officials Government liability Health care coverage and access Health facilities and institutions Health programs administration and funding Immunology and vaccination Infectious and parasitic diseases Minority health Racial and ethnic relations

Equal Access to Therapeutics Act

Introduced: February 7, 2022 See on congress.gov

Everywhere this bill has been 3 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Feb 8, 2022

Referred to the Subcommittee on Health.

Feb 7, 2022

Referred to the House Committee on Energy and Commerce.

Feb 7, 2022

Introduced in House

Plain-English summary Congressional Research Service

Equal Access to Therapeutics Act

This bill prohibits using race or ethnicity as a factor in decisions about an individual's access to COVID-19 treatments (e.g., monoclonal antibody therapies).

Specifically, the Department of Health and Human Services (HHS) may not adopt any policy or guidance that allows race or ethnicity to be factored into such decisions. Furthermore, the Secretary of HHS shall be personally liable for the death of any individual who is denied access to COVID-19 treatments pursuant to a prohibited policy or guidance.

The bill also prohibits hospitals or other health care providers that have policies restricting access to COVID-19 treatments based on race or ethnicity from receiving federal funds.

What's happening now February 8, 2022

Referred to the Subcommittee on Health.

Committees of jurisdiction 2